ʻO Onglisa: nā loiloi e pili ana i ka hoʻohana ʻana i ka lāʻau lapaʻau, ʻōlelo ʻānō

ʻO Onglisa kahi lāʻau lapaʻau no nā maʻi maʻi, ʻo ke ʻano ikaika o nā saxagliptin. ʻO Saxagliptin kahi lāʻau lapaʻau i kauoha ʻia no ka mālama ʻana i ka maʻi maʻi 2.

I loko o 24 mau hola ma hope o ka hoʻokele ʻana, ua pale ʻia nā hana a ka DPP-4. Inhibition o ka enzyme i ka wā e launa pū me ka glucose e hoʻonui i ka manawa 2-3 i ka pae o ka glucoseagon e like me peptide-1 (ma aneʻi GLP-1) a me ka glucose-e hilinaʻi i ka insulinotropic polypeptide (HIP), e hōʻemi ana i ka hoʻoliʻi o ka glucoseagon a hoʻoikaika i ka pane ʻana o nā cell beta.

I ka hopena, hoʻonui ka ʻikepili o ka insulin a me C-peptide i ke kino. Ma hope o ke hoʻokuʻu ʻia ʻana o nā insulin a nā cell beta o ka pancreas a me ka glucagon mai nā pūpū alpha, ua hoʻemi nui ʻia ka wikiwiki o ka glycemia a me ka glycemia postprandial.

Pehea ka palekana a me ka hoʻohana pono ʻana o ka saxagliptin i loko o nā ʻano like ʻole i hoʻopaʻa ʻia paʻa i loko o nā hoʻopaʻa noiʻi-plebo ka pālua, e pili ana i ka poʻe maʻi me ka 4148 e loaʻa ana me ka maʻi mellitus type 2.

I ka wā o nā noiʻi, ua ʻike nui ʻia ka hoʻomaikaʻi ʻana i ka hemoglobin glycated, ka wikiwiki o ka plasma plasma a me ka glucose postprandial. ʻO nā mea maʻi i lawe ʻole mai i ka monoprint saxagliptin i lawe ʻia i nā hopena i manaʻo ʻia ua hoʻonohonoho pū ʻia i nā lāʻau lapaʻau e like me ka metformin, glibenclamide a me thiazolidinediones.

Nā hōʻike hoʻokolohua o nā maʻi a me nā kauka: 4 mau pule ma hope o ka hoʻomaka ʻana o ka hoʻōla, loaʻa wale ka saxagliptin, hoʻemi ka pae o ka hemoglobin glycated, a ua emi ka hoʻoliʻi ʻana o ka glucose glucose ma hope o 2 mau pule.

Nā huaʻamau like i hoʻopaʻa ʻia i loko o kahi hui o nā mea maʻi i kuhikuhi ʻia i ka lāʻau hoʻohui me ka hoʻohui ʻana o ka metformin, glibenclamide a me thiazolidinediones; hana nā analogues i loko o ka hanana like.

I nā kūlana a pau, ʻaʻole i ʻike ʻia ka hoʻonui ʻia ʻana o ka paona kino o nā maʻi.

Ke noi ongliza

Ua hōʻike ʻia ka lāʻau lapaʻau i nā mea maʻi me ka maʻi o ke ʻano maʻi type 2 i kēlā mau kūlana:

Me ka monotherapy o kēia lāʻau lapaʻau i hui pū me ka hana kino a me ka lāʻauʻai,
Me ka hui pū ʻana me ka metformin,
I ka haʻalele ʻana o ka hana o ka monotherapy me ka metformin, derivatives o ka sulfonylurea, thiazolidinediones ma ke ʻano he lāʻau lapaʻau hou.

ʻOiaiʻo ka lāʻau o ka ʻenekini i hana i ka nui o nā haʻawina a me nā hoʻokolohua, ʻo ka loiloi e pili ana i ka hōʻoluʻolu, hiki ke hoʻomaka wale ke ʻano ma lalo o ka mālama ʻana o kahi kauka.

Nā maʻi hoʻohālikelike i ka hoʻohana ʻana o onglise

No ka mea e hoʻopilikia pono ai ka lāʻau i ka hana o nā beta a me nā ʻāpana alpha, e hoʻoikaika i kā lākou hana, ʻaʻole hiki ke hoʻohana mau. Ua pale ʻia ka lāʻau.

I ka wā hāpai, hānau a hānau keiki.
ʻO nā poʻe'ōpio ma lalo o 18 makahiki.
ʻO nā mea maʻi me ka maʻi diabetes mellitus type 1 (ʻaʻole i aʻo ʻia ka hana).
Me ka maʻi lapaʻau.
Me ka ketoacidosis maʻi maʻi.
ʻO nā mea maʻi me ka galactose congenital intolerance.
Me ka naʻauao pilikino i kekahi o nā ʻano o ka lāʻau.

ʻAʻohe hihia e hoʻowahāwahā ʻia nā kauoha no ka lāʻau lapaʻau. Inā kānalua paha e pili ana i ka palekana o kona hoʻohana, pono e koho ʻia nā mea pale a i ʻole kekahi ʻano loea e hoʻohana ai.

Hana ʻia ʻo Dosage a me ka hoʻokele

Hoʻokele ʻia ʻo Onglisa ma ke ʻano, me ka ʻole o ka ʻōlelo i ʻai. ʻO ka awelika hāmeʻa maʻamau i kēlā me kēia lā o ka lāʻau lapaʻau me 5 mg.

Inā lawe ʻia ke ʻano hui lāʻau, ʻae ʻole ka loli o ka lā maʻamau o ka saxagliptin, ua kūʻokoʻa ka nui o ke ʻano o ka metformin a me nā deralona sulfonylurea.

I ka hoʻomaka ʻana o ka hui hui ʻana me ka hoʻohana ʻana i ka metformin, e hōʻike ʻia ka nui o nā lāʻau lapaʻau.

Onglisa - 5 mg i ka lā,
Metformin - 500 mg i kēlā me kēia lā.

Inā ʻike ʻia kahi ʻano kūpono ʻole, pono ke hoʻoponopono ʻia ka nui o ka metformin, hoʻonui ʻia.

Inā paha, no kekahi kumu, ua nalowale ka manawa o ka lawe ʻana i ka lāʻau lapaʻau, pono ke lawe e ka mea maʻi i ka paila. ʻAʻole pono kēlā me ke kānalua i ka pāpālua i kēlā me kēia lā.

No ka poʻe maʻi e loaʻaʻole ka hopena o ka renal e like me ka mea e hoʻopiʻi nei, ʻaʻole pono ke hoʻoponopono i ke ʻano o ka onglise. Me nā hana o ka renal o ke ʻano hōʻona a me ke ʻano paʻakikī o ka onglis e lawe ʻia i nā liʻiliʻi liʻiliʻi - 2,5 mg hoʻokahi i ka lā.

Inā hana ʻia ka hemodialysis, lawe ʻia ka onglisa ma hope o ka hopena o ke kau. ʻAʻole i ʻike ʻia ka hopena o ka saxagliptin i nā maʻi e hana ana i ka dialysis peritoneal. No laila, ma mua o ka hoʻomaka ʻana i ka mālama ʻana me kēia lāʻau lapaʻau, pono e nānā ʻia kahi loiloi kūpono o ka hana o ka peʻahi.

Me ka hikiʻole o ka ate, hiki ke hoʻopaʻa palekana iā onglise i ka maʻa i hōʻike ʻia - 5 mg i kēlā me kēia lā. No ka mālamaʻana i nā maʻi maʻi maʻi, ua hoʻohana ʻia ka onglise i loko o ia ʻano like. Akā e hoʻomanaʻo ʻia ʻo ka lilo ʻana o ka pilikia o ka hiki ʻana o ka hoʻomaʻamaʻa ʻana i ka papa i kēia ʻano maʻi o ka maʻi maʻi.

ʻAʻohe kumu ʻike a ʻike haʻawina koʻikoʻi o nā hopena o ka lāʻau lapaʻau ma luna o nā mea maʻi ma lalo o 18 makahiki o kona mau makahiki. No laila, no nā poʻe ʻōpio me ke ʻano maʻi type 2, ua koho ʻia nā analogues me kekahi mea ikaika.

Ke koi nei i ka hoʻokaʻina o ka onglise e koi ʻia inā ka lāʻau lapaʻau ʻia i ka manawa like me ka potent inhibitors. I kēia:

ketoconazole
paulele
atazanavir
ailuaina
igraconazole
nelfinavir
ritonavir
saquinavir a me telithromycin.

No laila, ʻo ka palena nui o kēlā me kēia lā he 2.5 mg.

Nā hiʻohiʻona o ka mālamaʻana i nā wahine hāpai a me nā hopena

ʻAʻole i aʻo ʻia i ka hopena o ka lāʻau lapaʻau i ka papa o ka hapai ʻana, a inā paha e hiki ke komo i loko o ka waiū umauma, no laila, ʻaʻole i kuhikuhi ʻia ka lāʻau lapaʻau i ka manawa o ka hānai ʻana a me ka hānai i ka pēpē. Hoʻomaopopo ʻia e hoʻohana i nā mea ʻē aʻe a i ʻole e pau ai ka ʻokiʻoki.

ʻO ka maʻamau, ma hope o nā iniha a me nā manaʻo o ka hui hoʻohui, ʻoluʻolu ʻia ka lāʻau lapaʻau, i nā hihia loaʻa ʻole, e like me ka hōʻoia ʻana o nā loiloi, hiki ke ʻike ʻia kēia:

Lohea
ʻOihana Gastroenteritis,
Nā Aliʻi
ʻO ka hoʻokumu ʻana o nā maʻi nui o ka lāli
ʻO nā maʻi lēpaʻi o ka ʻōnaehana genitourinary.

Inā he hoʻokahi a oi aku paha nā hōʻailona, pono ʻoe e hoʻokuʻu i ka lāʻau a hoʻoponopono i ka dosage.

Wahi a nā loiloi, ʻoiai inā hoʻohana ʻia ka onglise i kahi manawa lōʻihi ma nā papa hana i ʻoi aku i nā manawa he 80 i hōʻike ʻia, ʻaʻohe hōʻailona o nā mea make. E hoʻoneʻe i ka lāʻau lapaʻau mai ke kino ma ka hihia inā hiki i kahi hoʻohālikelike, hoʻohana ʻia ke ʻano geomdialysis.

He aha hou aʻe e ʻike

ʻAʻole i kuhikuhi ʻia ʻo Onglis me ka insulin a i loko o ka triple therapy me nā metformin a me thiazolididones, no ka mea, ʻaʻole i lawe ʻia nā noi ʻana o kā lākou pilina. Inā hōʻeha ka mea maʻi i ka maʻi a me ka hiki ʻole i ka renal ka hopena, pono e hōʻemi ʻia ka nui o ka lā i kēlā me kēia lā. Diabetics me ka maluhia renal functioning e nānā mau ana i ke kūlana o nā keiki i ka wā o ka mālama ʻana.

Ua hoʻokumu ʻia e hiki i ka derivatives sulfanilurea ke hoʻonāukiuki i ka hypoglycemia. I mea e pale ai i ka hopena o ka hypoglycemia, pono ke hoʻoponopono ʻia i ka lāʻau o sulfanilurea i hui pū ʻia me ka hanana onglise. ʻO ia, hoʻemi.

Inā loaʻa i ka mea maʻi ka mōʻaukala o ka hypersensitivity i kekahi mau mea paʻa like ʻole DPP-4, ʻaʻole i kuhikuhi ʻia ka saxagliptin. No ka palekana a me ka hana pono o ka mālama ʻana i nā poʻe maʻi (ma lalo o 6 mau makahiki) me kēia lāʻau lapaʻau, ʻaʻohe ʻōmole i kēia hihia. Ua ʻae ʻia ʻo ʻOnglisa a hana i ke ʻano like me nā maʻi maʻi ʻōpio.

No ka mea i loko o ka huahana nā lactose, ʻaʻole kūpono ia no ka poʻe i komo i ka intolerance congenital i kēia ʻano mea, nele i ka lactose, maʻi malabsorption glucose-galactose.

ʻO ka hopena o ka lāʻau lapaʻau i ka hiki ke lawe i nā kaʻa a me nā lako ʻē aʻe e koi ai i kahi kiʻekiʻe o ka nānā ʻana, ʻaʻole i aʻo piha ʻia.

ʻAʻohe hopena contraindications e alakaʻi nei i kahi kaʻa, akā e hoʻomanaʻo ʻia i waena o nā hopena ʻaoʻao e hoʻohālikelike ai nā ʻeha a me nā hōʻeha.

Hoʻopili pū me nā lāʻau ʻē aʻe

Wahi a nā haʻawina loiloi, ʻo ka liʻiliʻi o ka hopena o ka pilina ma waena o nā onglises a me nā lāʻau ʻē aʻe, inā e lawe pū ʻia i ka manawa like, he liʻiliʻi nō ia.

ʻAʻole hoʻokumu nā kānaka ʻepekema i ka hake ʻana, ka inu ʻona, ka hoʻohana ʻana i nā lāʻau lapaʻau homeopathic, a i ʻole kaʻai ʻana i ka meaʻai i ka hopena o ka lāʻau lapaʻau, ma muli o ka nele o ka noiʻi ma kēia wahi.

E hoʻokuʻu i ke ʻano a me ka ʻano

ʻO ke ʻano huaʻala o ka hoʻokuʻu ʻana o Onglis i nā pā kihi ʻoniʻoni: hoʻopuni, biconvex, ua hoʻopili ʻia nā ʻatikala me ka wai polū, 2,5 mg i kēlā me kēia - mai ke aniani a hiki i ka melemele, ke kākau ʻia “2.5” ma ka ʻaoʻao hoʻokahi, a ““ 4214 ", 5 mg i kēlā me kēia - pink, ma ka ʻaoʻao hoʻokahi i ka palapala" 5 ", ma ka ʻaoʻao -" 4215 "(10 pcs. I nā blisters, i loko o kahi pahu pahu 3 blisters).

Helu 1 papa:

mea hoʻonaʻauao: saxagliptin (i ke ʻano o ka hydrochloride saxagliptin) - 2,5 a i ʻole 5 mg,
ʻO nā mea kōkua: lactose monohydrate - 99 mg, cellulose microcrystalline - 90 mg, sodium croscarmellose - 10 mg, magnesium stearate - 1 mg, hoʻonāola o 1M o ka waikila hydrochloric - i nui ka nui.
ʻūhā: Opadry II keokeo (polyvinyl alekino - 40%, titanium dioxide - 25%, macrogol - 20,2%, talc - 14,8%) - 26 mg, Opadry II ʻānela (no nā papa he 2.5 mg) polyvinyl alkohol - 40%, nā carbon dioxide - 24.25%, macrogol - 20.2%, talc - 14,8%, kīpana ka hao puaʻa (E172) - 0.75% - 7 mg, Opadry II ulana (no nā papa 5 mg) polyvinyl alekue - 40%, titanium dioxide - 24,25%, macrogol - 20,2%, talc - 14,8%, kalele waiona okside ulaula (E172) - 0.75% - 7 mg,
ke aniani: Opacode uliuli - (45% shellac in ethyl alkohol - 55,4%, FD&C Blue # 2 / indigo carmine pigment alumni - 16%, n-butyl alkohol - 15%, propylene glycol - 10,5%, isopropyl alkohol - 3% , 28% ammonium hydroxide - 0.1%) - i lawa nui.

Lapaʻau lāʻau

ʻO Saxagliptin kahi papa koho hoʻoiho hoʻoiho hou ʻana a dipeptidyl peptidase-4 (DPP-4) inhibitor. Ma ke ʻano 2 mellitus maʻi 'āina, alakaʻi kāna alakaʻi i kahi pani o ka hana o ka DPP-4 enzyme no 24 mau hola. Ma hope o ka nānāʻana i nā glucose, ka pale o DPP-4 e alakaʻi i ka hoʻonui ʻana o ka 2-3 i ka nui o ka hoʻomehana o ka glucose i hilinaʻi ʻia o ka insulinotropic polypeptide (HIP) a me ka peptide-1 (GLP-1), he mahuahua i ka pane ʻana i ke kūpaʻa e pili ana i ka glucose a hoʻōla i ka hoʻoliʻiliʻi o ka glucoseagon, kahi e hoʻonui ai i ka piʻi C-peptide a me ka insulin.

ʻO ka hōʻemi ʻana i ka hoʻokuʻu ʻana o ka glucagon mai nā kōpena alpha pancreatic a me ka hoʻokuʻu ʻana o ka insulin i ka pancreatic beta cells e alakaʻi i ka emi ʻana o ka wikiwiki o ka glycemia postprandial a me ka glycemia.

A ma muli iho o nā haʻawina hoʻokele plasebo, ua ʻike ʻia ʻo ka lawe ʻana iā Ongliza e hele me ka hoʻomaikaʻi nui ʻana ma ka helu wikiwiki ʻana i ka pāʻina plasma glucose (GPN), hemoglobin glycosylated (HbA)_1c) a me ka glucose koko postprandial (BCP) hoʻohālikelike i ka hoʻohālikelike ʻia me ka kāohi.

ʻO ka poʻe i ʻike ʻole i hiki ke hoʻokō i ka pae glycemic target ke lawe ʻana i ka saxagliptin e like me ka monotherapy e ʻōlelo ʻia i nā metformin, thiazolidinediones a i ʻole glibenclamide. Ke lawe nei me 5 mg o ka saxagliptin, e emi ana ka HbA_1c kaulana ma hope o 4 wiki, GPN - ma hope o 2 pule. I ka poʻe maʻi i loaʻa saxagliptin i hui pū me ka metformin, thiazolidinediones a i ʻole glibenclamide, ua ʻike ʻia kahi emi like.

E kūʻē i ke kiʻi ʻana o ka lawe ʻana iā Onglisa, ʻaʻole i ʻike ʻia kahi hoʻonui o ke kino ma ke kino. ʻO ka hopena o ka saxagliptin ma ka lipid profile ua like like ia me kahi pletebo.

Lapaʻau lāʻau

I nā limahana olakino a me nā maʻi me nā maʻi maʻi type 2, ʻike ʻia nā lāʻau lapaʻau like ʻole o ka saxagliptin a me kāna metabolite koʻikoʻi.

Hoʻopili koke ʻia ka waiwai ma hope o ke kaʻe waha i ka ʻōpū haki. He C C_max (ka uka nui o kahi waiwai) o ka saxagliptin a me ka nui o ka metabolite i loko o ka plasma e loaʻa ma mua o 2 mau hola a me 4 mau hola, kēlā. Me ka hoʻonui ʻia ʻana o kahi maʻi, he hoʻonui hoʻi i ka C_max a me AUC (ʻo ka wahi ma lalo o ka pihi i ka manawa paʻa) o ka waiwai a me kāna metabolite koʻikoʻi. Ma hope o hoʻokahi ka wai o 5 mg o ka saxagliptin e nā mea hana olakino ololi, nā kumukūʻai awelika o C_max saxagliptin a me kāna hana metabolite i loko o ka plasma he 24 ng / ml a me 47 ng / ml, ʻo nā waiwai AUC he 78 ng × h / ml a me 214 ng × h / ml, kēlā.

ʻO ka lōʻihi maʻamau o ka T hope_1/2 (hapalua-ola) o ka saxagliptin a me kāna hana koʻikoʻi he 2.5 mau hola a he 3.1 mau hola, kēlā me kēia, ka nui o ka waiwai o ka inhibition T_1/2 Plasma DPP-4 - 26.9 mau hola.Hana o ka hui o ka plasma DPP-4 no ka liʻiliʻi he 24 mau hola ma hope o ka lawe ʻana i ka saxagliptin e pili pū me kāna mea pili nui no DPP-4 a lōʻihi ka paʻa ʻana iā ia. Kuhi ʻia ka hoʻohui ʻia o nā waiwai a me kāna metabolite koʻikoʻi i ka manawa lōʻihi me ka neʻe o ka hoʻokele 1 mau manawa i kēlā me kēia lā ʻaʻole i mālama ʻia. ʻO ka hilinaʻi o ka clearance saxagliptin a me kāna metabolite koʻikoʻi ma ka pākuʻi o kēlā me kēia lā a me ka lōʻihi o ka lapaʻau i ka wā e lawe ai i ka lāʻau lapaʻau 1 manawa i kēlā lā i kēia lā ma ka inanahi like o 2.5-400 mg no nā lā 14 ʻaʻole i ʻike ʻia.

Ma hope o ka lawelawe waha, ʻaʻole i emi iho ma lalo o 75% o ka nui i lawe ʻia ʻia. ʻO ka ʻai ʻana ma ka pharmacokinetics o saxagliptin ʻaʻole i hoʻopilikia nui ʻia. ʻO nā kīʻaha momona kiʻekiʻe e pili ana i ka C_max ʻaʻohe mea nui, akā loaʻa nā waiwai AUC ma ka hoʻohālikelike ʻana me ka hoʻonui wikiwiki ʻana e 27%. Ke lawe nei i ka lāʻau lapaʻau me ka meaʻai, hoʻohālikelike ʻia me ka hoʻokē ʻai, ʻo ka manawa e hiki ai i ka C ke piʻi ma kahi o 30 mau minuke_max. ^ E Ha yM. ʻAʻole loaʻa ka manaʻo koʻikoʻi o kēia mau loli.

Saxagliptin a me kāna kaila metite hoʻopaʻa paʻa i nā protein serum i ka liʻiliʻi. I kēia mea, hiki ke manaʻo ʻia me nā loli me ka loli o ka pūnao o ka serum koko i mālama ʻia i loko o ka renal a i ʻole hepatic insufficiency, ʻaʻole ia e kuhi ʻia ka saxagliptin.

Ka hana nui ʻia o ka waiwai me ka komo ʻana o ka cytochrome P450 3A4 / 5 isoenzymes (CYP 3A4 / 5). Ma kēia hihia, ua hoʻokumu ʻia ka metabolite koʻikoʻi nui, ka hopena pale mai ka DPP-4 i ʻelua mau manawa haʻahaʻa ma mua o ka saxagliptin.

Saxagliptin me ka ʻoi a me ka urine a hoʻokuʻu ʻia. ʻO ka hoʻomaʻemaʻe kino ākea ākea o ka waiwai ma kahi o 230 ml / min, ʻo ka kānana glomerular awelika ma kahi o 120 ml / min. ʻO ka hoʻomaʻamaʻa Renal no ka metabolite koʻikoʻi ka hoʻohālikelikeʻana i nā helu hoʻohālikelike o ka kānana glomerular.

ʻO ke kumukūʻai AUC o ka saxagliptin a me kāna metabolite koʻikoʻi me ke kūleʻa papau a me 1,2 nā manawa he kiʻekiʻe, ʻoi aku ka nui, ma mua o nā mea maʻi me nā hana renalistist ʻole. ʻAʻole piʻi nui kēia hoʻonui ʻana i nā waiwai AUC, a ʻaʻole pono ke hoʻoponopono ʻia.

I ka hana ʻole ʻana a me ka maikaʻi o ka renal, a me ka poʻe i nā maʻi me ka hemodialysis, nā waiwai o ka AUC o ka waiwai a me kāna metabolite nui he 2.1 a me 4 mau manawa ʻoi aku ke kiʻekiʻe. Ma kēia pili ʻana i kēlā me kēia lā ka nui o kēia maʻi o nā mea maʻi e ʻoi aku ma kahi o 2,5 mg i loko o ka 1 pāʻai. I nā hihia no ka hana hepatic maʻi lēwa, ʻaʻole i ʻike ʻia ka loli o ka nui o ka maʻi i loko o ka pharmacokinetics o saxagliptin a, no laila, ʻaʻole pono ka hoʻoponopono ʻana.

Nā ʻokoʻa koʻikoʻi o nā maʻi i loko o ka pharmacokinetics o saxagliptin i nā maʻi maʻi 65-80 mau makahiki i hoʻohālikelike ʻia me nā mea maʻi o kahi mau makahiki ʻōpio ʻaʻole i ʻike ʻia. ʻOiai ka mea e pono ai i ka hoʻoponopono hoʻoponopono ʻia no kēia pūʻulu o nā maʻi, pono ia e noʻonoʻo i ka kiʻekiʻe kiʻekiʻe o ka hoʻemi ʻana o ka hana hana ʻole.

Nā hōʻailona no ka hoʻohana ʻana

Noi ʻia ʻo Onglisa no ka mālama ʻana i ka maʻi mellitus type 2 i ke ʻano he mea hana e hoʻomaʻamaʻa ai a me ka meaʻai i mea e hoʻomaikaʻi ai i ka mana glycemic.

Hiki ke kuhikuhi ʻia ka lāʻau lapaʻau e like me kēia:

monotherapy
Hoʻomaka ka hoʻomaka ʻana me nā metformin,
Hoʻohui i ka monotherapy me thiazolidinediones, metformin, sulfonylurea derivatives i nā hihia me ka nele o nā mālamalama glycemic i ka wā o ka mālama ʻana.

Nā ʻōkuhi no ka hoʻohana ʻana i nā Onglises: ke ʻano a me ka helu ʻana

Lawe ʻia ʻo Onglisa ma ke kino, me ka manaʻo ʻole o ka meaʻai.

ʻO ka paʻu i ʻōlelo ʻia he 5 mg ma ka 1 pāʻai.

Ke lawe ʻia nei i ka hui pū ʻana, hoʻohana ʻia ʻo Onglisa me ka metformin, sulfonylureas a i ʻole thiazolidinediones.

I ka hoʻomaka ʻana o ka lāʻau hoʻohui me metformin, ʻo kona ʻano mua o kēlā me kēia lā he 500 mg. I nā hihia o ka pane ʻole ʻana, hiki ke hoʻonui ʻia.

Inā ʻaʻole he hapa o Onglisa, pono nō e kiʻi ʻia i ka wikiwiki, akā naʻe, ʻaʻole i lawe ʻia ʻelua pane i loko o 24 mau hola.

ʻO ka lākau i kēlā me kēia lā no ka poʻe maʻi me ka maikaʻi ʻole o ka maikaʻi ʻole o ka renal (me ka cleinine clearance ≤ 50 ml / min), a me nā mea maʻi ma ka hemodialysis, he 2.5 mg ma ka 1 dosis. Pono e lawe ʻia ʻo Ongliz ma hope o ka pau ʻana o ka hālāwai hemodialysis. ʻAʻole i aʻo ʻia ka hoʻohana ʻana i ka lāʻau i nā maʻi ma luna o ka dialysis peritoneal. Ma mua o ka hoʻomaka ʻana / i ka wā o ka papa hana, e noi ʻia e loiloi i ka hana moloka.

ʻO Ollisa kahi i ʻōlelo ʻia i kēlā me kēia lā i hui pū ʻia me indinavir, tapizodone, ketoconazole, atazanavir, ritonavir, clarithromycin, itraconazole, nelfinavir, saquinavir, telithromycin a me nā mea paʻa ikaika CYP 3A4 / 5 he 2.5 mg.